<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>548-ZIDOVUDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ZIDOVUDINE " rxcui="11413">
<ATC code="J05AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AMPHOTERICIN B " rxcui="732">
<ATC code="A01AB04" />
<ATC code="A07AA07" />
<ATC code="G01AA03" />
<ATC code="J02AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the amphotericin B administered intravenously:

increase of the hematological toxicity (addition of effects of bone marrow toxicity)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent CBC.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>548-ZIDOVUDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ZIDOVUDINE " rxcui="11413">
<ATC code="J05AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DAPSONE" rxcui="3108">
<ATC code="D10AX05" />
<ATC code="J04BA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the hematological toxicity (addition of effects of bone marrow toxicity)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent CBC</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>548-ZIDOVUDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ZIDOVUDINE " rxcui="11413">
<ATC code="J05AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLUCYTOSINE" rxcui="4451">
<ATC code="D01AE21" />
<ATC code="J02AX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the hematological toxicity (addition of effects of bone marrow toxicity)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent CBC</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>548-ZIDOVUDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ZIDOVUDINE " rxcui="11413">
<ATC code="J05AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="GANCICLOVIR" rxcui="4678">
<ATC code="J05AB06" />
<ATC code="S01AD09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the hematological toxicity (addition of effects of bone marrow toxicity)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Stop the zidovudine temporarily; CBC, and reintroduce, if possible, the zidovudine in weak doses.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>548-ZIDOVUDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ZIDOVUDINE " rxcui="11413">
<ATC code="J05AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIBAVIRIN" rxcui="9344">
<ATC code="J05AB04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the medications together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>548-ZIDOVUDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ZIDOVUDINE " rxcui="11413">
<ATC code="J05AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="STAVUDINE" rxcui="59763">
<ATC code="J05AF04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>548-ZIDOVUDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ZIDOVUDINE " rxcui="11413">
<ATC code="J05AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects, especially hematological ones, of the zidovudine due to decrease of its metabolism by the valproic acid</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring. A CBC checking for anemia should be done during the course of the first two months of the administration of these substances together. </COMMENT>
</INTERACTION>
</INTERACTIONS>
